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ABSTRACT
The osprey (Pandion haliaetus) is a well‐known sentinel of environmental contamination, yet no studies have traced
pharmaceuticals through the water–fish–osprey food web. A screening‐level exposure assessment was used to evaluate the
bioaccumulation potential of 113 pharmaceuticals and metabolites, and an artificial sweetener in this food web. Hypothetical
concentrations in water reflecting “wastewater effluent dominated” or “dilution dominated” scenarios were combined with
pH‐specific bioconcentration factors (BCFs) to predict uptake in fish. Residues in fish and osprey food intake rate were used to
calculate the daily intake (DI) of compounds by an adult female osprey. Fourteen pharmaceuticals and a drug metabolite with a
BCF greater than 100 and a DI greater than 20 mg/kg were identified as being most likely to exceed the adult human
therapeutic dose (HTD). These 15 compounds were also evaluated in a 40 day cumulative dose exposure scenario using first‐
order kinetics to account for uptake and elimination. Assuming comparable absorption to humans, the half‐lives (t1/2) for an
adult osprey to reach the HTD within 40 days were calculated. For 3 of these pharmaceuticals, the estimated t1/2 in ospreys was
less than that for humans, and thus an osprey might theoretically reach or exceed the HTD in 3 to 7 days. To complement the
exposure model, 24 compounds were quantified in water, fish plasma, and osprey nestling plasma from 7 potentially impaired
locations in Chesapeake Bay. Of the 18 analytes detected in water, 8 were found in fish plasma, but only 1 in osprey plasma (the
antihypertensive diltiazem). Compared to diltiazem detection rate and concentrations in water (10/12 detects, <method
detection limits [MDL]–173 ng/L), there was a lower detection frequency in fish (31/233 detects, <MDL–2400 ng/L); however
when present in fish, all values exceeded the maximum diltiazem concentration found in water. Diltiazem was found in all 69
osprey plasma samples (540–8630 ng/L), with 41% of these samples exceeding maximum concentrations found in fish.
Diltiazem levels in fish and osprey plasma were below the human therapeutic plasma concentration (30 000 ng/L). Effect
thresholds for diltiazem are unknown in ospreys at this time, and there is no evidence to suggest adverse effects. This
screening‐level exposure model can help identify those compounds that warrant further investigation in high‐trophic level
species. Integr Environ Assess Manag 2015;11:118–129. © 2014 SETAC
Keywords: Bioaccumulation
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INTRODUCTION
In parallel with human population growth and a myriad of
veterinary and human health uses, pharmaceuticals and their
metabolites primarily enter the environment through wastewater from bulk drug production, sewage plants and septic
systems, and in biosolids applied to agricultural lands (Kolpin
et al. 2002; Ramirez et al. 2009). The development of advanced
analytical techniques and widespread monitoring has revealed
the presence of pharmaceuticals in a variety of environmental
All Supplemental Data may be found in the online version of this article.
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Screening‐level exposure assessment

matrices (sediments, sewage sludge, water, and ﬁsh). Pharmaceuticals may not be completely removed by traditional
wastewater treatment systems, and with constant wastewater
inputs, even labile compounds may exhibit pseudo‐persistence
in surface waters (Daughton and Ternes 1999; Celiz et al.
2009). Their detection in the environment has raised concerns
about bioaccumulation, transfer through the food web, and
potential effects that pharmaceutical “cocktails” may elicit on
ecosystems.
Understanding ecological risks of pharmaceuticals to free‐
ranging wildlife (amphibians, reptiles, birds, and mammals)
remains a major research need (Boxall et al. 2012), the one
exception being the nonsteroidal anti‐inﬂammatory drug
(NSAID) diclofenac used to treat livestock. Diclofenac use
resulted in nontarget poisoning and endangerment of several
species of Asian vultures feeding on carcasses of cattle that had
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been treated with this drug (Oaks and Watson 2011). The
catastrophic effects of diclofenac on old world vultures resulted
in detailed investigations of several NSAIDs in birds. A recent
workshop evaluated the risk of pharmaceuticals to wildlife and
identiﬁed major information gaps including the need to conduct
food web exposure modeling and environmentally realistic risk
assessments (Arnold et al. 2013). Hernout et al. (2011) also
suggested that prioritizing chemicals (e.g., metals, pesticides,
pharmaceuticals) in a food web framework before intensive and
costly investigation would be beneﬁcial to natural resource
managers and policymakers.
Ospreys (Pandion haliaetus) are a high trophic level species
that have served as sentinels of ecosystem health and
environmental change (Grove et al. 2009). Their eggs and
blood are excellent matrices to document spatial and temporal
trends and to elucidate exposure, bioaccumulation, and
biomagniﬁcation of contaminants. Ospreys are strictly piscivorous and this aspect makes their diet easy to monitor and link to
sources of localized contaminant exposure. Their diet can vary
with salinity (Glass and Watts 2009), prey availability, and
trophic position and can range from anadromous ﬁsh in
polyhaline regions to nonmigratory ﬁsh in oligohaline waters.
Ospreys are adaptable to human landscapes and can be found
nesting in highly industrialized and urbanized areas and even in
proximity to wastewater treatment plants (WWTPs).
To date, no studies have examined the bioaccumulation of
pharmaceuticals and their fate in the water‐ﬁsh‐osprey food
web. This study describes a framework and the ﬁndings of a
screening‐level exposure assessment to estimate the daily and
cumulative 40 day intake of pharmaceuticals that are being
analyzed by some environmental research laboratories (Du
et al. 2012; Furlong et al. 2014). This was complemented by
empirical analyses of 23 compounds and an artiﬁcial sweetener
analyzed in water and blood plasma of ﬁsh and osprey nestlings
from sites located along potentially impaired waterways in
Chesapeake Bay.

METHODS
Screening‐level exposure model: Daily intake
The daily intake (DI) of 113 pharmaceuticals, metabolites,
and an artiﬁcial sweetener (Table S1) by an adult female osprey
was calculated to determine which compounds reached or
exceeded the human therapeutic dose (HTD) (assumes
comparable intestinal absorption for both ospreys and
humans) (Figure 1). These compounds are quantiﬁed at the
US Geological Survey National Water Quality Laboratory
(Furlong et al. 2014) and some of these compounds are
analyzed in ﬁsh plasma (Du et al. 2012). Three hypothetical
exposure regimes (10, 100, and 1000 ng/L) were chosen
(ranging from “dilution dominated” high ﬂow to “wastewater
efﬂuent dominated” low ﬂow) (Brooks et al. 2006) and
modeled across 3 pH values (pH 6, pH 7, pH 8) that are
representative of surface water gradients at ﬁeld study sites.
The pH consideration is important, because the drugs
examined are all potentially ionizable and their bioconcentration factors (BCFs) are pH‐speciﬁc and dependent on log D (a
measure taking into account ionized and un‐ionized forms of a
molecule) (Meylan et al. 1999; Fu et al. 2009). These factors
can inﬂuence bioaccumulation and toxicity in ﬁsh (Valenti
et al. 2009, 2011, 2012), and ultimately, their absorption
(bioaccessibility) in the gastrointestinal tract of birds. Predicted
BCFs for each substance (ACS 2014) were used to calculate

119

the quantity of a pharmaceutical accumulated in a generic ﬁsh
in 24 hours (Berninger et al. 2011).
Calculated pharmaceutical residues in ﬁsh from each
scenario were used to estimate the DI for a 1568 g adult female
osprey (USEPA 1993). Due to the complexities in modeling
cumulative exposure of a growing osprey nestling (e.g., logistic
growth plateauing at 40 days, changing food intake, and
metabolic demands, etc.), a 40 day exposure assessment for an
adult osprey was conducted. Food intake rate (FIR) was
estimated 2 ways. The ﬁrst estimate used osprey bite size and
body weight (BWt) to calculate a FIR of 329 g of ﬁsh wet weight
(ww) per day (Poole 1985; USEPA 1993). The second estimate
used dry weight (dw) consumption rates based on the
relationship between BWt and metabolic energy for birds
(FIR g dw/day¼ 0.648BWt0.651) (Nagy 1987; USEPA 1993).
The FIR for an adult female osprey (77.94 g ﬁsh dw/day)
converted to ww (assuming 75% water content for a generic
ﬁsh) was 312 g/day. These 2 estimates yielded similar results
and the metabolic‐based estimate was selected for use. The DI
(mg pharmaceutical/kg Bwt) was calculated using Equation 1
DI ¼ ðresidue in fishÞðFIRÞ=ðkg BWtÞ:

ð1Þ

The DIs for varying degrees of absorption were compared to
the oral HTD for an adult. Human therapeutic doses were
obtained as the minimum daily dose to exert a therapeutic
effect (RxList 2008; FDA 2012; Drugsite Trust 2014).
Screening‐level exposure model: 40 day cumulative intake
To estimate cumulative body burden of ospreys, assumptions
included that diet was the principal exposure route, BWt and
FIR were constant, and intestinal absorption was comparable
between ospreys and humans. Clearance was incorporated
assuming a ﬁrst‐order kinetic elimination equation to calculate
total exposure (i.e., mg/kg BWt) because the majority of
ionizable pharmaceuticals follow this type of elimination
(Bardal et al. 2011). Using DI (t ¼ 1 d), exposure (E) oscillated
following a saw‐tooth pattern between peak (Epeak) and trough
(Etrough)
Epeak ¼ ðDIremaining Þekt þ DI ðjust after mealÞ;

ð2Þ

Etrough ¼ ðDIremaining Þekt þ ðDIÞekt ðjust before a mealÞ;
ð3Þ
t1=2 ¼ lnð2Þ=k ðhalf-life elimination constantÞ:

ð4Þ

There are limited data on the half‐lives (t1/2) of pharmaceuticals in birds to apply in these equations. To place the
40 day exposure into perspective, the drug t1/2 in ospreys
needed to reach or exceed the HTD within 40 days at most
extreme scenario (1000 ng/L concentration, pH 8, complete
absorption) was back calculated. Equation 3 (daily exposure at
nadir) was used to conservatively estimate cumulative daily
body burden. The back calculated t1/2 for ospreys was
compared to the t1/2 in humans (Ebadi 2008; Wishart
et al. 2008; FDA 2012).
Empirical pharmaceutical exposure data
Study sites were selected in urbanized areas in proximity to
WWTPs, combined sewer outﬂows, and efﬂuent dominated
low ﬂow sites. These sites include the Susquehanna River (MD,
PA), Back River (MD), James River (VA), and the US
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Figure 1. Theoretical screening‐level exposure assessment framework used to model the daily intake (DI) for an osprey.

Environmental Protection Agency (USEPA) designated Regions of Concern (Baltimore Harbor [MD], Anacostia River/
middle Potomac [DC, MD, VA], and the Elizabeth River
[VA]), all of which appear on the 303d list for impaired
waterways (Figure 2) (USEPA 2013). Sampling was undertaken during osprey nesting seasons of 2011, 2012, and 2013. The
Paul S. Sarbanes Ecosystem Restoration Project at Poplar Island
(MD), a remote mid‐Bay location, was used as a reference site.
Duplicate water samples were collected from 12 select
sampling sites (2–3 locations along a stretch of the Susquehanna
River, Back River, Anacostia/middle Potomac Rivers, James
River, and at Poplar Island). Surface water samples were
collected in clean 4 L amber glass jugs. Field blanks were taken
by opening an empty jar to account for other sources of
contamination. Water quality parameters (pH, dissolved O2,
temperature, conductivity) were measured concurrently (YSI
Multimeter Yellow Springs OH). Water samples were stored
on wet ice and shipped overnight to Baylor University.
All procedures involving ﬁsh and ospreys were conducted
under approval of the Institutional Animal Care and Use
Committees of the US Geological Survey (USGS) and the

University of Maryland, and appropriate scientiﬁc collection
permits. Game camera (Bushnell 8MP Trophy Cam, Overland
Park, KS) images of prey items delivered to osprey nests, direct
observations, and identiﬁcation of scraps were used to
reconstruct osprey diet and identify target species for sampling.
Based on osprey diet reconstruction, a combination of gizzard
shad (Dorosoma cepedianum), catﬁsh (blue catﬁsh Ictalurus
furcatus, brown bullhead Ameiurus nebulosus, and channel
catﬁsh Ictalurus punctatus), and carp (Cyprinus carpio) were
sampled on the Susquehanna, Anacostia/middle Potomac, and
James Rivers. Atlantic menhaden (Brevoortia tyrannus), striped
bass (Morone saxatilis), and white perch (Morone americana)
were sampled at the more saline Poplar Island site, and a
combination of carp, catﬁsh, gizzard shad, and white perch
were sampled on Back River. These ﬁsh species reﬂect different
trophic levels ranging from primary consumers (herbivorous)
such as Atlantic menhaden and gizzard shad, to secondary
consumers (carnivorous) including white perch and striped
bass, to catﬁsh and carp (omnivorous) representing a combination of both primary and secondary consumers. Fish were
captured by electroshocking in upriver sites. At Poplar Island,
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Figure 2. Map detailing the locations of Chesapeake Bay study sites.

ﬁsh were captured using a midwater trawl and a commercial
pound net. Plasma was sampled from the 2 to 3 dominant prey
ﬁsh species found at each site that fell within the osprey foraging
size range (25–35 cm) (Poole 1989). All ﬁsh (n ¼ 233) were
anesthetized (MS222, tricane methanesulfonate), weighed,
measured, and 1 to 2 mLs of blood were sampled using a
heparinized syringe. Fish blood was stored on wet ice and
transported to the USGS‐Leetown Science Center in WV. The
blood was centrifuged at 2000 g at 4°C for 10 min on the same
day of collection. Plasma was harvested for pharmaceutical
analyses and stored at 80°C. Fish tissue was saved for analysis
of organic contaminants as part of a concurrent study.
Osprey nests were identiﬁed in mid‐March along a 25 to
35 km stretch of river. A sample egg was collected for analysis
of legacy contaminants and nests were visited weekly to
determine reproductive success as part of a concurrent study.
Once nestlings reached 40 to 45 days of age, a single chick was

brieﬂy removed from the nest (<10 min). Body weight and
culmen length were measured, and a 5 to 7 mL brachial blood
sample was drawn into a heparinized syringe. Samples were
stored on wet ice and centrifuged at 1500 g at 4°C for 10 min on
the same day of collection. Plasma was harvested and samples
(n ¼ 69) were stored at the USGS‐Patuxent Wildlife Research
Center at 80°C. All plasma samples were shipped frozen to
Baylor University for the quantiﬁcation of pharmaceuticals.
Analysis of pharmaceuticals
A suite of 23 pharmaceuticals and metabolites and an artiﬁcial
sweetener (Tables S1 and S2) were quantiﬁed in water and
plasma samples from ﬁsh and osprey nestlings via isotopic dilution
liquid chromatography‐tandem mass spectrometry (LC‐MS/
MS). These compounds included analgesics (acetaminophen,
codeine), antibiotics (erythromycin, sulfamethoxazole, trimethoprim), an anticoagulant (warfarin), antidepressants (paroxetine,
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ﬂuoxetine, sertraline, and primary metabolites norﬂuoxetine
and desmethylsertraline), an antihistamine (diphenhydramine),
antihypertensives (atenolol, diltiazem, propranolol), anti‐
inﬂammatories (celecoxib, diclofenac), an antilipemic (gemﬁbrozil), an antiseizure (carbamazepine), a parasiticide (ivermectin), psychostimulants (diazepam, methylphenidate), a stimulant
(caffeine), and an artiﬁcial sweetener (sucralose; conservative
tracer of efﬂuent discharges) (Soh et al. 2011).
For water, sample ﬁltration and extraction generally followed
previously described protocols (Du et al. 2014). A mixture of
24 internal standards (deuterated analogues of target compounds, except for ivermectin for which abamectin was the
internal standard) and 5 mL of methanol was added to 500 mL
of each water sample before extraction and acidiﬁcation
(pH adjusted with 100 mL of 85% [v/v] phosphoric acid)
(Lajeunesse et al. 2008). Resulting concentrations of internal
standards were approximately 100 ng/g. Samples were subsequently loaded onto strong cation‐exchange cartridges (Strata‐
SCX, 500 mg; Phenomenex, Torrance, CA) preconditioned
with 4 mL of methanol and 8 mL of nano‐pure water. Each
cartridge was washed with 4 mL of HCl (0.1 N) and 4 mL of
methanol, followed by elution of the 5 antidepressant serotonin
reuptake inhibitors with 6 mL of 5% (v/v) NH4OH in methanol.
Extraction of 19 other analytes generally followed a previously
reported protocol (Vanderford and Snyder 2006). Each sample
(500 mL subsample) was spiked with a mixture of internal
standards and loaded onto a preconditioned HLB cartridge
(200 mg, Waters, Milford, MA). These loaded cartridges were
air‐dried and subsequently eluted with 5 mL methanol followed
by 5 mL 10:90 (v/v) methanol‐methyl tertiary butyl ether. The
eluate from 2 separate extractions was evaporated to dryness
under a stream of N and reconstituted in 1 mL of chromatographic mobile phase (i.e., methanol‐0.1% [v/v] aqueous
formic acid). Before LC‐MS/MS analysis, samples were
sonicated for 1 min and ﬁltered using Pall Acrodisc hydrophobic
Teﬂon Supor membrane syringe ﬁlters (13 mm diameter;
0.2 mm pore size; VWR Scientiﬁc, Suwanee, GA).
For plasma samples, a slightly modiﬁed extraction method
was used (Fick, Lindberg, Parkkonen et al. 2010). An aliquot of
ﬁsh and osprey plasma (typically 1 mL), combined with the
same mixture of internal standards that was used for water, was
diluted to 5 mL using 0.1% (v/v) aqueous formic acid and
mixed thoroughly by sonication. The mixture was loaded on
preconditioned (5 mL of methanol and 5 mL of nano‐pure
water) HLB SPE cartridges (200 mg, Waters). Each cartridge
was air‐dried and subsequently eluted with 5 mL of methanol.
The eluate was reconstituted, and analytes were quantiﬁed by
LC‐MS/MS as previously described (Du et al. 2012).
For water and ﬁsh plasma, method detection limits (MDLs)
were less than 11 ng/L with the exception of ivermectin and
sucralose (Table S2). Osprey plasma from the reference site,
spiked with the mixture of internal standards, was used to
determine MDLs, which were similar to that of water and ﬁsh
(Table S2). For quality control purposes, 1 pair of matrix spike
samples and 1 method blank sample was added for each batch
analysis. Spike recoveries ranged from 81% to 111% in water,
81% to 113% in ﬁsh, and 81% to 89% in ospreys.
Statistical analyses
For the daily and 40 day screening‐level exposure models, DI
and half‐life elimination constants were estimated using
Microsoft Excel. For empirical exposure data, concentrations
of pharmaceuticals and an artiﬁcial sweetener were ﬁrst
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recovery corrected and only values above the MDL were
reported. If the analyte was present in all samples, the
arithmetic mean and standard deviation were obtained using
SAS (SAS Institute, NC). If an analyte was detected in only 1 of
the 2 duplicate water samples, one randomly selected value was
included in the statistical analysis. If analytes were detected in
over half (but not all) of the samples at a study location, the
Kaplan‐Meier method was used to estimate an interval that
contains the theoretical mean (Helsel 2005, 2009).
Parametric statistics were conducted for those analytes detected
in all samples. Continuously distributed analyte concentrations in
water, and ﬁsh and osprey plasma were tested for homogeneity of
variance (Levene’s test) and normality (Shapiro‐Wilk test). In 2
instances, variables were log or square root transformed to correct
for normality or heterogeneous variances. A 1‐way analysis of
variance followed by Tukey’s honestly signiﬁcant difference
method for multiple comparisons was performed (a ¼ 0.05). For
those sites with nondetects, a generalized Wilcoxon nonparametric test was used (Helsel 2005).
For all detectable compounds, a hazard quotient (HQ) was
calculated by dividing the maximum concentration found in
ﬁsh or osprey plasma by the human therapeutic plasma
concentration (Cmax). The larger the HQ value, the greater
the potential for a compound to exert a pharmacological effect
in ﬁsh or ospreys.

RESULTS
Screening‐level exposure model
Of 114 compounds, 31 had a BCF less than or equal to 1.00
(Table S1). These 31 compounds plus the bronchodilator
tiotropium (no BCF available) were excluded from the model.
Of the 83 remaining compounds, 15 had both a BCF greater
than 100 and an estimated DI greater than 20 mg/kg‐day and are
predicted to have the greatest potential to bioaccumulate. The
calculated DIs for these 15 compounds at concentrations of 10,
100, and 1000 ng/L in an adult female osprey are presented in
Table 1. At concentrations of 1000 ng/L water at pH 8, the DI
of orlistat, fenoﬁbrate, tamoxifen, and loperamide would be 1.1
to 4.4 times greater than the oral HTD. Based on the
information in Table 1, orlistat is the only compound that still
exceeds the HTD even if the intestinal absorption in ospreys
was only half that of humans (12 198 mg/kg BWt‐day, 2.4 times
greater than the HTD). Pharmaceutical concentrations in water
and pH values selected in the model were environmentally
realistic (analyte concentrations in Chesapeake Bay range from
0.029 to 10 249 ng/L and site pH ranged from 6.15 to 8.34)
(Tables 3 and S3).
Cumulative 40 day exposure model
For the top 15 compounds (BCF > 100, DI > 20 mg/kg
BWt‐day), the theoretical half‐life (calculated from the
half‐life elimination constant, k) for an osprey to reach the
HTD within a 40 day period ranged from 1 to 231 days. For this
subset of pharmaceuticals, the half‐lives in humans ranged from
0.04 to 7 days. Notably, the half‐lives in ospreys for fenoﬁbrate,
tamoxifen and ezetimibe were less than that in humans, with
the HTD being exceeded in just 3 to 7 days (Table 1).
Empirical assessment of pharmaceuticals in water, fish,
and osprey
Of the 24 analytes measured, 17 were detected in water and 8
of these were also detected in ﬁsh (Tables 2, S3, and S4).
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Table 1. DI at 3 water concentrations and t1/2 to accumulate an HTD within 40 days for 15 pharmaceuticals compared to human values
t1/2 ospreys to exceed
HTD 100% absorptiona

DI osprey (100% absorption)
(mg/kg BWt‐day)a

Rank
1

Compound
Orlistat

BCF pH 8
123 000

2

Fenofibrate

3

Piperonyl butoxide

10 ng/L

100 ng/L

1000 ng/L

pH 8

pH 8

pH 8

244

2440

HTD (mg/kg BW)
a

24 396
a

15 100

29.9

299

2995

2400

4.76

47.6

476
a

1000 ng/L
pH 8

t1/2 humans (d)

1.79

0.04–0.08

1714

0.42 (HTD in 3 d)

0.83

Topical

NAb

NA

5143
a

a

4

Tamoxifen

797

1.58

15.8

158

143

1.00 (HTD in 4 d)

5–7

5

Ketoconazole

646

1.28

12.8

128

2857

22.8

0.14

6

Ezetimibe

589

1.16

11.6

117

143

1.19a (HTD in 7 d)

0.79–1.25

b

7

Iminostilbene

556

1.10

11.0

110

5714

34.3

0.08–2.71

8

Loratadine

538

1.06

10.7

107

143

1.27

0.35

9

Loperamide

519

1.03

10.3

103a

57.1

0.67

0.45

10

Promethazine

358

0.71

7.10

71.1

357

4.07

0.67–0.79

11

Diltiazem

343

0.68

6.80

68.0

2571

231

0.12–0.18

12

Raloxifene

327

0.65

6.50

65.0

857

11.3

1.15

13

Dextromethorphan

228

0.45

4.52

45.2

571

11.3

0.05–0.16

14

Desmethylsertraline

213

0.42

4.20

42.3

NA

NA

2.58–4.33

15

Sertraline

142

0.28

2.82

28.2

357

11.5

1.04–1.08

DI ¼ daily intake; HTD ¼ human therapeutic dose; NA ¼ not applicable; not ingested for therapeutic uses or a metabolite of a parent compound.
a
Indicate the estimated DI or t1/2 for ospreys exceeds HTD or human t1/2.
b
Iminostilbenes are a group of antiseizure drugs that includes carbamazepine and oxcarbamazepine. HTD and half‐lives are given based on the lowest dose in this
group that is needed for a therapeutic effect.

Diltiazem was the only compound detected in all 3 matrices
(Table 3, all values presented on a ng/L basis). When compared
to the human therapeutic plasma concentration (Cmax), all
detected compounds had a HQ less than or equal to 0.08.
In water, concentrations were averaged from the 2 to 3
sampling sites per tributary. There were 73 out of 77 instances
where the analyte was detected in the duplicate water samples
and the median relative percent difference between samples
was 12.02%. Samples were collected from the reference site
each year of the study, but diltiazem was only detected in water
samples in 2011 and 2012. At Back River, 18 analytes were
detected in water with concentrations being 2 to 154 times
greater than other sites. Carbamazepine, diltiazem, sulfamethoxazole, diphenhydramine, and caffeine were detected in water
at all intensively sampled sites. Statistical analysis revealed that
the Anacostia/middle Potomac Rivers had the greatest
carbamazepine (log transformed) and caffeine concentrations
in water (Back River excluded from analysis as there was only a
single sample), followed by the James, Poplar Island, and
Susquehanna (p < 0.04). There were no differences in diltiazem concentrations in water among all 5 sites.
Although 7 pharmaceuticals and sucralose were found in ﬁsh,
detection frequency was low, rarely exceeding half of the
samples per site. Thus, parametric statistical analyses could not
be conducted among analytes, ﬁsh species, and sites (Table S4).
By inspection of these data, diphenhydramine and diltiazem
were present in ﬁsh from all study sites. Both the Anacostia/

middle Potomac and Back Rivers had the largest suite of
pharmaceuticals detected. Diltiazem was found in 13% of ﬁsh
samples and present in all species, with the greatest plasma
concentration (2.4 ng/mL) found in a catﬁsh collected on the
Susquehanna (Table 3).
Diltiazem was detected in all 69 osprey nestling plasma
samples (1.6–24.6 times greater than the MDL). Osprey
nestlings on the Anacostia/middle Potomac, Baltimore Harbor,
and Back River had higher (p < 0.04) diltiazem plasma
concentrations (square root transformed) compared to the
James, Elizabeth, Susquehanna Rivers, and the Poplar Island
reference site. Plasma diltiazem concentrations at Poplar were
higher than those on the Elizabeth and James Rivers
(p < 0.007). For the Potomac River, which had osprey nests
evenly spaced downriver from Blue Plains WWTP, diltiazem in
nestling plasma did not exhibit a spatial concentration gradient
(p > 0.35).

DISCUSSION
Screening‐level exposure assessment
Whereas several studies have examined uptake of pharmaceuticals from water by ﬁsh (Brown et al. 2007; Ramirez
et al. 2009), their transfer to high trophic level wildlife has not
been evaluated. The likelihood for a broad suite of potentially
ionizable pharmaceuticals to bioaccumulate in a water–ﬁsh–
osprey food web was modeled using their concentration in
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Table 2. Summary of compounds detected in water and fish across study sitesa
Analgesic

Site/class

Antibiotic

Anticoagulant

Acetaminophen Codeine Sulfamethoxazole Trimethoprim Erythromycin

Warfarin

Antihistamine

Psychostimulant

Diphenhydramine Methylphenidate Diazepam

Poplar Island
þ

Water

þ

Atlantic menhaden
Striped bass

þ

White perch

þ

Anacosita/middle Potomac Rivers
Water

þ

þ

þ

þ

þ

Catfish sp.

þ

Gizzard shad

þ

Carp

þ

þ

Back River
Water

þ

þ

þ

þ

þ

þ

þ

þ

þ

þ

Catfish sp.
þ

Gizzard shad

þ

Carp

þ

White perch

þ

James River
þ

Water

þ

þ

Catfish sp.

þ

Gizzard shad

þ

Susquehanna River
þ

Water

þ

Catfish sp.
Gizzard shad
Antihypertensive
Atenolol

Diltiazem

Anti‐inflammatories
Propanolol

Celecoxib

Diclofenac

Antilipemic

Antiseizure

Artificial Sweetener

Stimulant

Gemfibrozil

Carbamazepine

Sucralose

Caffeine

þ

þ

þ

þ

þ

þ

Poplar Island
Water

þ

Atlantic menhaden

þ

Striped bass

þ

White perch

þ

þ

Anacosita/Middle Potomac Rivers
Water

þ

þ

Carp

þ

þ

Catfish sp.
Gizzard shad

þ

þ

þ
þ

þ
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Table 2. (Continued)
Antilipemic

Antiseizure

Artificial Sweetener

Stimulant

Atenolol

Antihypertensive
Diltiazem

Propanolol

Anti‐inflammatories
Celecoxib

Diclofenac

Gemfibrozil

Carbamazepine

Sucralose

Caffeine

þ

þ

þ

þ

þ

þ

þ

þ

þ

þ

þ

Back River
Water
Catfish sp.

þ

Gizzard shad

þ

þ
þ

Carp
White perch
James River
Water

þ

þ

Catfish sp.

þ

Gizzard shad

þ

þ

þ

þ

Susquehanna River
þ

Water
Catfish sp.

þ

þ

þ

Gizzard shad

þCompound detected.

a

water, pH‐speciﬁc BCF and FIR of an adult female osprey.
Those compounds with high pH‐speciﬁc BCFs and long half‐
lives near low ﬂow point sources (i.e., low dilution scenario)
were predicted to exceed the HTD.
This screening‐level assessment identiﬁed a subset of 15 of
114 compounds that warrant further investigation based on
their potential to exceed the HTD. Over a narrow range of pH
(6–8), there was little effect on the BCF of 6 of these
compounds (orlistat, fenoﬁbrate, piperonyl butoxide, ezetimibe, iminostilbene, and loratadine), with BCFs ﬂuctuating by
less than 20% (Table S1). Although ionizable at pH extremes
(low or high pKa), these 6 compounds were in their neutral
state from pH 6–8 and predicted to be the most bioaccumulative. It has been suggested that compounds with such
characteristics could evoke pharmacological responses and
possibly toxicity in invertebrates and ﬁsh at their isoelectric
point (Ebadi 2008; Rendal et al. 2011). The remaining 10
compounds (mean pKa 8.37) are not ionizable until pH
exceeds environmentally relevant conditions. The use of pH‐
speciﬁc BCFs appears to be a valuable tool to identify and
prioritize pharmaceuticals and metabolites that have the
greatest potential to bioaccumulate at environmentally relevant
conditions.
An estimate of the half‐life is required to model ﬁrst‐order
kinetic elimination of drugs over a speciﬁc period of time and
provides a measure of the persistence of a xenobiotic. Based on
our screening‐level exposure model, HTDs for fenoﬁbrate,
tamoxifen, and ezetimibe were exceeded in adult ospreys at
theoretical half‐lives (0.24–1.19 days) that were less than their
half‐lives in humans (0.83–1.25 days) (Ebadi 2008; Wishart
et al. 2008). Such theoretical half‐lives are not unreasonable.
For the aforementioned compounds, it might be possible for an

osprey to accumulate a HTD within 3 to 7 days of exposure in a
low‐ﬂow scenario.
Uncertainty factors and model assumptions
There are a suite of model assumptions and sources of
uncertainty that inﬂuence DI. This model only takes into
account dietary exposure, which is generally acknowledged to
be the principal exposure route in ﬁsh‐eating birds
(USEPA 1993), and that the ingested compounds are absorbed
at a rate comparable to that of humans. Although this
assessment assumed a constant body weight and FIR, this is
unlikely because of variations in prey availability, tidal
inﬂuences, and movement of ﬁsh in relation to point source,
osprey foraging success, and sibling competition. Environmental factors, including weather and duration and intensity of
sunlight (UV and visible), can affect the compound before it
enters the prey and its disposition in both prey and predator.
There are a series of factors that must be considered in
extrapolating uptake (i.e., total tissue and plasma concentrations) and effect thresholds among species within a
vertebrate class (body weight and surface area [Davidson
et al. 1986], biochemical, genetic, physiological, and behavioral
factors [Dorrestein and Van Miert 1988; Toutain et al. 2010])
and are even more tenuous among classes.
Interspeciﬁc differences in drug absorption, distribution,
metabolism, and elimination can be used to place species
sensitivities into perspective. Once a compound is ingested, it is
subject to pH changes in the gut and intestines that can
inﬂuence a drug’s ionizable state. Although our model
accounted for environmentally relevant water pH and used
pH‐speciﬁc BCFs, it did not include the effects of digestive
tract pH. Of the compounds with the greatest potential for
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Table 3. Diltiazem concentrations in water, fish, and osprey on ng/L basis
Fish (ng/L plasma) Detects/n Mean  SD Extremes HQb

Site
Poplar Island

Water (ng/L)
Detects/n
Mean  SD
Extremes

Catfish

Gizzard
shad

Carp

Rockfish

Menhaden

Perch

Osprey
(ng/L plasma)
Detects/n
Mean  SDa
Extremes HQb

2/3

NS

NS

NS

3/17

1/10

1/10

13/13

—

—

—

2199  1524C

1.06–1.14c
<MDL–2.05

Anacosita/middle
Potomac Rivers

Back River

James River

Susquehanna River

<MDL–1800 <MDL–410 <MDL–410

2/3

0/30

3/33

1/18

1.08–1.62c

—

—

—

<MDL–2.47

—

<MDL–410 <MDL–330
0.01

0.01

605–4458

0.06

0.01

0.01

0.15

NS

NS

NS

13/13
4517  1384A

NS

NS

NS

3503–8630
0.29

1/1

1/2

1/9

0/9

—

—

—

173

<MDL–350

<MDL–420

0.01

0.01

3/3

8/27

3/27

5.85  2.51

—

—

912  225D

2.96–7.49

<MDL–770

<MDL–570

537–1355

0.03

0.02

0.05

2/2

9/18

0/18

1.67  0.45

—

—

1434  372C,D

1.35–1.99

<MDL–2400

–

4049–2099

0.08

NS

NS

0/5

7/7

—

—

2353  1207B,C

—

—

1049–4288
0.29

NS

NS

NS

NS

NS

NS

NS

NS

12/12

10/10

0.07

Additional sites where
only osprey nestlings
sampled
Elizabeth River

6/6
966  352D
564–1320
0.04

Baltimore Harbor/
Patapsco River

8/8
3786  714A,B
2885–5110
0.17

— ¼ indicates no mean calculated, contaminant was detected in fewer than half of the samples; HQ ¼ hazard quotient; MDL ¼ method detection limit; NS ¼ not
sampled because fish species was not a large component of osprey diet at a particular site; SD ¼ standard deviation;
a
Means with different captial letter superscripts are significantly different (p < 0.05).
b
HQ is the upper extreme concentration found in fish or osprey plasma divided by the human therapeutic plasma concentration (Cmax) for diltiazem (30 000 ng/L).
c
If nondetects were present in <50% of the samples, the Kaplan‐Meier method was used to estimate the extremes of the mean followed by a generalized Wilcoxin
nonparametric test.
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bioaccumulation (Table 1), 9 have a pKa greater than 7.5 and 2
have a pKa less than 6.9, thus remaining in their neutral state in
the small intestine favoring increased bioaccessibility. A great
deal is known about metal bioaccessibility in birds (Martinez‐
Haro 2009), but far less is known about the absorption
efﬁciency and potential interspeciﬁc differences of pharmaceuticals and many other organic compounds in the avian
gastrointestinal tract. Additional information is required before
bioaccessibility can be included in the model.
Pharmaceuticals have much shorter environmental half‐lives
than persistent organic pollutants, although studies suggest
some pharmaceuticals can exhibit pseudo‐persistence under
efﬂuent dominated scenarios (Daughton 2002; Brooks
et al. 2006). Furthermore, some pharmaceuticals may be
poorly metabolized by ﬁsh, resulting in increased potential for
bioaccumulation (Connors et al. 2013). Unlike mammals,
pharmacokinetic parameters (including t1/2) have been estimated for only a few classes of drugs used in disease prevention
and treatment (e.g., antibiotics, antifungals, antivirals, analgesics, parasiticides, and sedatives) in a limited number of avian
species (domestic poultry and waterfowl and companion
animals including psittacines) (Goetting et al. 2011;
Guzman 2014). However, for free‐ranging avian wildlife,
pharmacokinetic parameters are unknown, with the exception
of NSAIDs. Notably, diclofenac half‐lives vary by over an order
of magnitude among old world vultures (Accipitridae), new
world vultures (Cathartidae), and domestic poultry (Galliformes), and other NSAIDs exhibit a wide range of half‐lives
among orders of birds (Baert and Backer 2003; Naidoo
et al. 2008, 2009). Once a xenobiotic enters the body,
cytochrome P450s are the primary system used to metabolize
foreign compounds (phase I metabolism) with monooxygenase
activity varying across species, sex, age, diet (feeding guild),
season, and disease (Walker 1980). Notably, low monooxygenase activity is found in ﬁsh‐eating birds (Walker 1980; Toutain
et al. 2010).
Empirical findings in water and fish
Eighteen pharmaceuticals and an artiﬁcial sweetener were
detected in water samples from Chesapeake Bay. Frequency of
detection and concentrations were greatest in water samples
collected on the Back River, which receives appreciable WWTP
input (180 million gallons/day from 1.3 million residents from
Baltimore) (Baltimore County Watershed Management
Program 2012). Despite greater input from Blue Plains
WWTP and population size (330 million gallons/day from
2.1 million residents of the Washington District of Columbia
metropolitan area) (District of Columbia Water and Sewage
Authority 2014), concentrations were seemingly lower on the
Anacostia/middle Potomac Rivers.
Sulfamethoxazole, diphenhydramine, diltiazem, carbamazepine, sucralose, and caffeine were frequently detected in
water samples, and 3 of these (diphenhydramine, diltiazem,
and carbamazepine) were often detected in ﬁsh plasma (Tables
S3 and S4). In ﬁsh, detection frequency, concentrations, and
HQs were low and far less than critical environmental
concentrations hypothesized to cause pharmacological effects
in ﬁsh (Schwab et al. 2005; Fick, Lindberg, Tysklind
et al. 2010; Du et al. 2014). This is not unexpected as other
reports indicate that both sucralose and caffeine do not
bioaccumulate in ﬁsh. Sucralose was detected at lower
concentrations in ﬁsh than in water samples from the
Anacostia/middle Potomac Rivers and did not bioconcentrate
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(maximum detected concentration in ﬁsh/maximum detected
concentration in water ¼ 0.50; Tables S3 and S4). Notably
laboratory studies have reported a BCF less than 1 for sucralose
in zebraﬁsh (Danio rerio) (Lillicrap et al. 2011) and is not that
different from literature estimates (BCF ¼ 1, Table S1)
(ACS 2014). Of the compounds most frequently detected in
ﬁsh, our estimated BCFs were within an order of magnitude
compared to literature values presented in Table S1 (diphenhydramine: estimated 79.1 compared with literature value of
16.7; carbamazepine: 44.1 versus 16.2; diltiazem: 319 versus
343). Interestingly, antidepressants were not found in the
present study despite being detected in many urban rivers in
North America (Brooks et al. 2005; Ramirez et al. 2009;
Lajeunesse et al. 2011; Schultz et al. 2010).
Diltiazem was the only analyte detected in water, ﬁsh, and
biota. For diltiazem, concentrations in water were low (mean
2.44 ng/L), and with the exception of Back River (173 ng/L),
was generally an order of magnitude below those found in urban
inland waters of the United States and Sweden (36–1800 ng/L)
(Kolpin et al. 2002, 2004; Fick, Lindberg, Parkkonen
et al. 2010; Du et al. 2014). In Chesapeake Bay, diltiazem
ﬁsh plasma concentrations were 2 times greater than those
observed at 3 WWTPs in Sweden (MDL‐1000 ng/L) (Fick,
Lindberg, Parkkonen et al. 2010). Out of 10 commonly
used pharmaceuticals tested in Daphnia magna and
Japanese medaka (Oryzias latipes), diltiazem exhibited the
greatest acute toxicity (96 h LC50 ¼ 8.2 and 15.0 mg/L,
respectively) (Kim et al. 2007). The predicted no‐effect
concentration for diltiazem based on the lowest acute EC50
values was estimated to be 8.2 mg/L (Kim et al. 2007), which is
over an order of magnitude greater than the maximum value
observed in the Back River. Evaluating these data in a more
complete assessment should also include chronic responses
linked to therapeutic hazard (Brausch et al. 2012; Valenti
et al. 2012). The aquatic hazards and risk of diltiazem and
many other pharmaceuticals remain poorly characterized
(Brooks 2014).
Several interspeciﬁc differences in pharmaceutical bioaccumulation were found among ﬁsh species (Table S4). For
example, diltiazem was detected in channel catﬁsh, but not
gizzard shad from the Susquehanna River, whereas carbamazepine was observed in blue and channel catﬁsh, but again not
gizzard shad from the Anacostia/middle Potomac Rivers.
Spatial variations in ﬁsh migration patterns may explain such
differences in pharmaceutical bioaccumulation. For example,
anadromous gizzard shad migrate downstream to deeper waters
in the winter, whereas catﬁsh remain in upper estuarine sites
where they may be continuously exposed to wastewater
discharge. The inﬂuence of trophic position (e.g., herbivorous
gizzard shad and omnivorous catﬁsh) on pharmaceutical
bioaccumulation in ﬁsh is not well understood.
Empirical findings in osprey nestlings
This screening‐level exposure assessment suggests that only 3
of 24 analytes quantiﬁed in osprey plasma (diltiazem, sertraline,
and desmethylsertraline) are likely to exceed the HTD. Of
these 3, diltiazem has the highest pH‐speciﬁc BCF (343 at pH
8) and was detected in all osprey nestling plasma at low
concentrations (0.56–8.63 ng/mL plasma), with the maximum
value being 28% of the HTD. Although present in all osprey
samples, there were no overt signs (therapeutic or toxicological) observed in our companion study examining reproductive
success. Ospreys are thriving in Chesapeake Bay, including the
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most contaminated sites, and reproduction is generally
adequate to sustain stable populations (>1.15 ﬂedglings per
active nest) (Lazarus et al. 2012).
Of the 15 compounds identiﬁed in the screening‐level model
as having the greatest potential to bioaccumulate, 3 were
measured in osprey plasma (Table 1; diltiazem 11, desmethylsertraline 14, and sertraline 15), and only diltiazem was
detected. The accumulation of diltiazem and other antidepressants is theoretically pH‐dependent. The bioaccumulation
characteristics (partition coefﬁcients log p and log D at pH 8) of
sertraline (log p ¼ 5.08 and log D ¼ 3.60) and its metabolite
desmethylsertraline (log p ¼ 4.89 and log D ¼ 3.73), are not
unlike diltiazem (i.e., log p ¼ 4.73 and log D ¼ 3.90). Thus,
diltiazem may be bioaccumulating not only because of its high
pH‐speciﬁc BCF, but also because of other biological
characteristics including speciﬁc binding mechanisms. It is
clear that diltiazem concentrations were greatest in osprey
nestlings followed by ﬁsh and water concentrations. Across
sites, the maximum diltiazem concentrations in water, ﬁsh
plasma, and osprey plasma were averaged for each matrix to
approximate a biomagniﬁcation factor. Diltiazem concentrations in ﬁsh plasma were 21.6 times greater than those in water,
and osprey plasma concentrations were 4.71 times greater
than ﬁsh. It should be noted that the biomagniﬁcation factor
from ﬁsh to osprey most certainly varies with osprey diet
composition.

CONCLUSIONS
This screening‐level exposure assessment identiﬁed 15 out
of 113 pharmaceuticals and an artiﬁcial sweetener that warrant
further investigation in ﬁsh‐eating birds due to their high BCF
and DI. Some of these compounds might even exceed the
HTD. The antihypertensive drug diltiazem was detected in all
osprey nestling plasma samples in several tributaries of
Chesapeake Bay. Twelve additional analytes that were
predicted to bioaccumulate, but not measured in environmental samples should receive priority for further investigation.
Although diltiazem in ospreys did not exceed the HTD and
was well below the Cmax, our ﬁndings indicate that it can
bioaccumulate to levels that are over 4 times greater than
values in ﬁsh plasma. Even though empirical concentrations of
drugs in the present study are well‐below therapeutic levels for
humans, the paucity of effect threshold data for birds and lower
vertebrates makes interpretation of these observations challenging. Our knowledge of mammalian pharmacology can
assist in extrapolation of effects to wildlife (Huggett
et al. 2003), but in some (and hopefully rare) instances, birds
and other perhaps other classes of vertebrates may be sensitive
to low‐level environmental exposures (Oaks and Watson
2011).
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